Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER IMMUNOTHERAPY

Splitting signals drives CARs further

Nature Cancer volume 2, pages 873–875 (2021)Cite this article

Subjects

CAR T cell therapies have made great strides in the clinic; however, multiple hurdles limit the efficacy of this approach for solid tumors. A new study has developed an optimized, dual-targeting CAR T cell that overcomes several of these challenges by enhancing T cell persistence and reducing therapy escape due to antigen loss.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Dual CAR expression with split co-stimulation and a shared CD3ζ domain enhances CAR activity.

BioRender.com

References

  1. Carpenito, C. et al. Proc. Natl Acad. Sci. USA 106, 3360–3365 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Milone, M. C. et al. Mol. Ther. 17, 1453–1464 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. MacIver, N. J., Michalek, R. D. & Rathmell, J. C. Annu. Rev. Immunol. 31, 259–283 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. O’Sullivan, D. et al. Immunity 41, 75–88 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kawalekar, O. U. et al. Immunity 44, 380–390 (2016).

    Article  CAS  PubMed  Google Scholar 

  6. Hirabayashi, K. et al. Nat. Cancer https://doi.org/10.1038//s43018-021-00244-2 (2021).

  7. Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Nat. Biotechnol. 31, 71–75 (2013).

    Article  CAS  PubMed  Google Scholar 

  8. Shah, N. N. et al. Nat. Med. 26, 1569–1575 (2020).

    Article  CAS  PubMed  Google Scholar 

  9. Zah, E., Lin, M. Y., Silva-Benedict, A., Jensen, M. C. & Chen, Y. Y. Cancer Immunol. Res. 4, 498–508 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Heczey, A. et al. Mol. Ther. 25, 2214–2224 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Feucht, J. et al. Nat. Med. 25, 82–88 (2019).

    Article  CAS  PubMed  Google Scholar 

  12. Wherry, E. J. & Kurachi, M. Nat. Rev. Immunol. 15, 486–499 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Guedan, S. et al. J. Clin. Invest. 130, 3087–3097 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Boucher, J. C. et al. Cancer Immunol. Res. 9, 62–74 (2021).

    Article  CAS  PubMed  Google Scholar 

  15. Kofler, D. M. et al. Mol. Ther. 19, 760–767 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Tiffany R. King-Peoples & Avery D. Posey Jr.

  2. Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA

    Avery D. Posey Jr.

Authors
  1. Tiffany R. King-Peoples
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Avery D. Posey Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Avery D. Posey Jr..

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

King-Peoples, T.R., Posey, A.D. Splitting signals drives CARs further. Nat Cancer 2, 873–875 (2021). https://doi.org/10.1038/s43018-021-00257-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-021-00257-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research